TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1869847

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (750 mg every 12 h)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (Quinine treatment)
Number of subjects: 8
Study: 6342839

Group type: EXPERIMENTAL
Intervention: Propranolol therapy
Number of subjects: 3837

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 3837
Study: 30796477

Group type: EXPERIMENTAL
Intervention: Belief that urinary incontinence is normal for ageing
Number of subjects: 4446

Group type: COMPARATOR
Intervention: Belief that urinary incontinence is not normal for ageing
Number of subjects: 4446
Study: 30036440

Group type: EXPERIMENTAL
Intervention: Montelukast prophylaxis for 2 weeks before pollen season and throughout the season
Number of subjects: 57

Group type: COMPARATOR
Intervention: Montelukast during pollen season only (control group)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Montelukast prophylaxis
Number of subjects: 57
Study: 27151024

Group type: EXPERIMENTAL
Intervention: Recombinant human thrombopoietin (rhTPO) at a dose of 300 U/(kg·d) for a maximum of 14 days
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Recombinant human thrombopoietin (rhTPO)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Glucocorticoid (standard dose) for 28 days
Number of subjects: 96
Study: 24224779

Group type: EXPERIMENTAL
Intervention: Percutaneous radiofrequency ablation (RFA)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Hepatectomy
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both RFA and Hepatectomy
Number of subjects: 120
Study: 23027921

Group type: EXPERIMENTAL
Intervention: 90 mmol KHCO(3)/d
Number of subjects: 8

Group type: COMPARATOR
Intervention: High NaCl intake
Number of subjects: 8
Study: 19430043

Group type: EXPERIMENTAL
Intervention: Indapamide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 0

Group type: COMPARATOR
Intervention: Indapamide and Perindopril
Number of subjects: 0
Study: 17721372

Group type: EXPERIMENTAL
Intervention: Epaxal coadministered with DTPaHibIPV, oral polio vaccine, and measles‐mumps‐rubella vaccine (group A)
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Epaxal given alone (group B)
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Havrix Junior coadministered with DTPaHibIPV, oral polio vaccine, and measles‐mumps‐rubella vaccine (group C)
Number of subjects: 322

Group type: COMPARATOR
Intervention: Booster dose for all groups
Number of subjects: 322
Study: 15456470

Group type: COMPARATOR
Intervention: Esomeprazole 40 mg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg twice daily
Number of subjects: 0
Study: 12362006

Group type: EXPERIMENTAL
Intervention: Hyperbaric-oxygen treatment
Number of subjects: 152

Group type: COMPARATOR
Intervention: Normobaric-oxygen treatment
Number of subjects: 152
Study: 9438445

Group type: EXPERIMENTAL
Intervention: 1D MR myocardial tagging in healthy subjects (n=10)
Number of subjects: 17

Group type: COMPARATOR
Intervention: 1D MR myocardial tagging in patients with chronic pulmonary hypertension (n=7)
Number of subjects: 17
Study: 8079605

Group type: EXPERIMENTAL
Intervention: Birth center care (EG)
Number of subjects: 1230

Group type: COMPARATOR
Intervention: Standard obstetric care (CG)
Number of subjects: 1230
Study: 2480721

Group type: EXPERIMENTAL
Intervention: Usual 4‐hourly morphine dose
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 1102877

Group type: EXPERIMENTAL
Intervention: Maprotiline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30942011

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation at Zusanli (ST 36), 30 min every time, once every 8 h, until the end of the first bowel movement.
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group (conventional treatment only).
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation at Zusanli (ST 36).
Number of subjects: 110
Study: 28333292

Group type: EXPERIMENTAL
Intervention: 1500 IU hCG on the day of FET and 6 days after FET
Number of subjects: 450

Group type: COMPARATOR
Intervention: Normal saline on the day of FET and 6 days after FET
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: 1500 IU hCG
Number of subjects: 450

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 450

Group type: COMPARATOR
Intervention: hCG and normal saline
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: hCG
Number of subjects: 450
Study: 26156796

Group type: EXPERIMENTAL
Intervention: Butyrate enema (100 mmol sodium butyrate/L; 60 mL; n = 7)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (140 mmol 0.9% NaCl/L; 60 mL; n = 5)
Number of subjects: 12
Study: 22496275

Group type: EXPERIMENTAL
Intervention: Preventive medications (statins, antiplatelet therapy, beta-blockers, ACE inhibitors/ARBs)
Number of subjects: 15828
Study: 21899544

Group type: EXPERIMENTAL
Intervention: Methylsulfonylmethane (MSM) supplementation (50 mg/kg body weight)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (water)
Number of subjects: 18
Study: 18179672

Group type: EXPERIMENTAL
Intervention: Schema Focused Therapy (SFT)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Transference Focused Psychotherapy (TFP)
Number of subjects: 86
Study: 16479521

Group type: EXPERIMENTAL
Intervention: Neonatal vitamin A supplementation
Number of subjects: 4495

Group type: EXPERIMENTAL
Intervention: Maternal vitamin A supplementation
Number of subjects: 4495

Group type: EXPERIMENTAL
Intervention: All 3 vitamin A regimens
Number of subjects: 4495

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 4495
Study: 14685126

Group type: EXPERIMENTAL
Intervention: New classifications for diabetes and healthcare provision strategies
Number of subjects: 0
Study: 11070759

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate 10 mg
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate 20 mg
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate 20 mg-SR
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate 40 mg-SR
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate 80 mg-SR
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate 120 mg-SR
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 8629678

Group type: EXPERIMENTAL
Intervention: Isoetharine (5 mg)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Albuterol (2.5 mg)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Isoetharine
Number of subjects: 51
Study: 1571421

Group type: EXPERIMENTAL
Intervention: Renal ultrasonography during the acute phase of illness
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Renal ultrasonography after antimicrobial therapy
Number of subjects: 25
Study: 2865725

Group type: EXPERIMENTAL
Intervention: Stepped-care (SC)
Number of subjects: 10940

Group type: COMPARATOR
Intervention: Referred-care (RC)
Number of subjects: 10940
Study: 31335641

Group type: EXPERIMENTAL
Intervention: Hybrid emotion-focused exposure treatment (n = 58, 10-16 sessions)
Number of subjects: 115

Group type: COMPARATOR
Intervention: iCBT (n = 57; 8 treatment modules)
Number of subjects: 115
Study: 30295222

Group type: EXPERIMENTAL
Intervention: Refresher training session (R (+) group)
Number of subjects: 50

Group type: COMPARATOR
Intervention: No refresher training session (R (−) group)
Number of subjects: 50
Study: 27488944

Group type: EXPERIMENTAL
Intervention: Perindopril (10 mg daily)
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Amlodipine (5 mg daily)
Number of subjects: 227

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 227
Study: 24569062

Group type: EXPERIMENTAL
Intervention: Neurotip mounted Neuropen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plastic neurological wheel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison between Neurotip mounted Neuropen and plastic neurological wheel
Number of subjects: 0
Study: 22901886

Group type: EXPERIMENTAL
Intervention: 75 mg mepolizumab
Number of subjects: 621

Group type: EXPERIMENTAL
Intervention: 250 mg mepolizumab
Number of subjects: 621

Group type: EXPERIMENTAL
Intervention: 750 mg mepolizumab
Number of subjects: 621

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 621
Study: 20111599

Group type: EXPERIMENTAL
Intervention: ADMVA (1x10^7 pfu)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: ADMVA (5x10^7 pfu)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: ADMVA (2.5x10^8 pfu)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 18085837

Group type: COMPARATOR
Intervention: IANB plus mock buccal infiltration and mock lingual infiltration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IANB plus buccal infiltration and mock lingual infiltration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IANB plus mock buccal infiltration and lingual infiltration
Number of subjects: 0
Study: 16260891

Group type: EXPERIMENTAL
Intervention: Indomethacin (0.2 mg/kg, three doses at 12-hour intervals, infused continuously over 15 min)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 44

Group type: COMPARATOR
Intervention: Ibuprofen (10 mg/kg initial dose followed by two doses of 5 mg/kg each after 24 and 48 h, infused continuously over 15 min)
Number of subjects: 44
Study: 12226782

Group type: EXPERIMENTAL
Intervention: Real ESWT (low-energy shock wave therapy)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (energy-absorbing foil)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Real ESWT
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 11382863

Group type: EXPERIMENTAL
Intervention: Cholinergic REM sleep induction test (CRIT) with 10 mg galanthamine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 24
Study: 7589593

Group type: EXPERIMENTAL
Intervention: Breast-conserving therapy
Number of subjects: 2

Group type: COMPARATOR
Intervention: Mastectomy
Number of subjects: 2
Study: 2796881

Group type: EXPERIMENTAL
Intervention: 1.2 mg/kg of cimetropium bromide 1 hour before bottle
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 2.0 mg/kg of cimetropium bromide 1 hour before bottle
Number of subjects: 40
Study: 352152

Group type: EXPERIMENTAL
Intervention: Hydrocortisone 500 mg injected intravenously every 12 hours for four doses
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study: 30192070

Group type: EXPERIMENTAL
Intervention: Text message reminders
Number of subjects: 96

Group type: COMPARATOR
Intervention: Standard consultation (control group)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Pharmacist-led counseling
Number of subjects: 96
Study: 28874821

Group type: EXPERIMENTAL
Intervention: Sprint interval training (SIT)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Moderate-intensity continuous training (MICT)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both SIT and MICT
Number of subjects: 26
Study: 25488686

Group type: EXPERIMENTAL
Intervention: docetaxel (35 mg/m² days 1, 8, 15 every 4 weeks for four or six cycles)
Number of subjects: 299

Group type: COMPARATOR
Intervention: CMF (cyclophosphamide 600 mg/m², methotrexate 40 mg/m², fluorouracil 600 mg/m², days 1, 8)
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: docetaxel
Number of subjects: 299

Group type: COMPARATOR
Intervention: CMF
Number of subjects: 299
Study: 23352187

Group type: EXPERIMENTAL
Intervention: 1:10,000 BVA plus PT
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: 1:30,000 BVA plus PT
Number of subjects: 68

Group type: COMPARATOR
Intervention: Normal saline (NS) injection plus PT
Number of subjects: 68
Study: 20919993

Group type: EXPERIMENTAL
Intervention: Ischaemic postconditioning (postcon) with three episodes of 30-s inflation and 30-s deflation of the angioplasty balloon
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postconditioning in rats (three cycles of 10-s reperfusion and 10-s coronary re-occlusion)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selective iNOS inhibitor 1400W
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3-morpholinosydnonimine (ONOO- donor)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no postconditioning)
Number of subjects: 0
Study: 19698147

Group type: EXPERIMENTAL
Intervention: Specific acupoints of the stomach meridian
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Non-specific acupoints of the stomach meridian
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Specific acupoints of alarm and transport points
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Acupoints of the gallbladder meridian
Number of subjects: 120

Group type: COMPARATOR
Intervention: Drug (positive control) group
Number of subjects: 120

Group type: COMPARATOR
Intervention: Non-acupoint control group
Number of subjects: 120
Study: 16424063

Group type: EXPERIMENTAL
Intervention: Green tea catechins (GTCs) - 600 mg/d (three capsules of 200 mg each)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Green tea catechins (GTCs)
Number of subjects: 60
Study: 15557857

Group type: EXPERIMENTAL
Intervention: Nonpreserved timolol
Number of subjects: 73

Group type: COMPARATOR
Intervention: Timolol maleate gel-forming solution
Number of subjects: 73
Study: 12790983

Group type: EXPERIMENTAL
Intervention: Indoramin (20 mg, twice daily for 6 weeks)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Indoramin
Number of subjects: 23
Study: 9120495

Group type: EXPERIMENTAL
Intervention: Biexponential decay lesions (50 lesions)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Monoexponential decay lesions (70 lesions)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Correlation with disability
Number of subjects: 40
Study: 8292515

Group type: EXPERIMENTAL
Intervention: Oral megadose methylprednisolone (MDMP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intravenous immunoglobulin G (IV IgG)
Number of subjects: 20
Study: 2880161

Group type: EXPERIMENTAL
Intervention: Omeprazole 60 mg once daily
Number of subjects: 51

Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 51
Study: 30452394

Group type: EXPERIMENTAL
Intervention: Diagonal Active Stretching (DS)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Static Stretching (SS)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both groups (DS and SS)
Number of subjects: 24
Study: 30024811

Group type: EXPERIMENTAL
Intervention: Community Health Worker (CHW) intervention with cash incentives, supply chain support, and monthly clinical supervision.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Community Health Worker (CHW) intervention for diarrhea treatment.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no CHW intervention).
Number of subjects: 0
Study: 26867498

Group type: EXPERIMENTAL
Intervention: Amorolfine 5% nail lacquer (NL) alone
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Amorolfine 5% nail lacquer (NL) plus cosmetic nail varnish
Number of subjects: 48

Group type: COMPARATOR
Intervention: Both groups (Amorolfine 5% NL alone and NL plus cosmetic nail varnish)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Cosmetic nail varnish
Number of subjects: 48
Study: 24549549

Group type: COMPARATOR
Intervention: Antiarrhythmic drugs
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Number of subjects: 127

Group type: COMPARATOR
Intervention: Quality of life measures
Number of subjects: 127
Study: 22545894

Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloon (PCB) angioplasty
Number of subjects: 40

Group type: COMPARATOR
Intervention: Plain balloon angioplasty (BA)
Number of subjects: 40
Study: 19879276

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (1 x 2 g daily for 14 days)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Meropenem (3 x 1 g daily for 14 days)
Number of subjects: 40
Study: 17356989

Group type: EXPERIMENTAL
Intervention: Chronic Care Model (CCM) intervention
Number of subjects: 613

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 613
Study: 16238119

Group type: EXPERIMENTAL
Intervention: Novo‐Helisen Depot allergy vaccines for 3 years
Number of subjects: 56

Group type: COMPARATOR
Intervention: Conventional methods of treatment
Number of subjects: 56
Study: 12235690

Group type: EXPERIMENTAL
Intervention: Asthmatic group
Number of subjects: 23
Study: 10524722

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy over a period of 8 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: No changes to treatment status (Control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy
Number of subjects: 0
Study: 7788130

Group type: EXPERIMENTAL
Intervention: Zuclopenthixol
Number of subjects: 34

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 34
Study: 2092963

Group type: EXPERIMENTAL
Intervention: Zolpidem 20 mg
Number of subjects: 42

Group type: COMPARATOR
Intervention: Flunitrazepam 2 mg
Number of subjects: 42
Study: 655936

Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Timolol + other adrenergic amines (norepinephrine, epinephrine)
Number of subjects: 0
Study: 30318240

Group type: EXPERIMENTAL
Intervention: USG-guided SLN block bilaterally with 2.5 ml of 2% lignocaine along with GA (Group L)
Number of subjects: 40

Group type: COMPARATOR
Intervention: General anesthesia (GA) alone (Group C)
Number of subjects: 40
Study: 27802910

Group type: EXPERIMENTAL
Intervention: Indianapolis Vocational Intervention Program (IVIP)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Support therapy group (SG)
Number of subjects: 64
Study: 25996273

Group type: EXPERIMENTAL
Intervention: Personalized diabetes risk assessments and point-of-care measurement of HbA(1c) during retinal ophthalmologic visits.
Number of subjects: 1756

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 1756
Study: 22868407

Group type: EXPERIMENTAL
Intervention: PSNB in combination with an obturator nerve block (obturator group, n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: PSNB alone (control group, n = 20)
Number of subjects: 40
Study: 21271182

Group type: EXPERIMENTAL
Intervention: Isotonic solution (Gatorade(®))
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Water
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control (200 mL water)
Number of subjects: 99
Study: 19478547

Group type: EXPERIMENTAL
Intervention: Phenylephrine 2.5% and tropicamide 1% (group 0)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Phenylephrine 10% and tropicamide 1% (group 1)
Number of subjects: 58
Study: 16460486

Group type: EXPERIMENTAL
Intervention: Silybum marianum (600 mg or 1200 mg/day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 15321699

Group type: EXPERIMENTAL
Intervention: L-NMMA infusion
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Vitamin C co-infusion
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: CRP serum levels correlation
Number of subjects: 75
Study: 11571244

Group type: EXPERIMENTAL
Intervention: alpha‐galactosidase A therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9610942

Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg with alcohol (0.75 g ethanol/kg b.wt.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zolpidem 15 mg with alcohol (0.75 g ethanol/kg b.wt.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zolpidem with alcohol (0.75 g ethanol/kg b.wt.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 0
Study: 7821190

Group type: EXPERIMENTAL
Intervention: 4 injections per day with a pen injector
Number of subjects: 78
Study: 2468877

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 31

Group type: COMPARATOR
Intervention: Clonidine
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 31

Group type: COMPARATOR
Intervention: Verapamil
Number of subjects: 31

Group type: COMPARATOR
Intervention: Chlorthalidone
Number of subjects: 31
Study: 31809878

Group type: EXPERIMENTAL
Intervention: Behavioral activation (BA)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Standard intervention
Number of subjects: 183
Study: 29651853

Group type: EXPERIMENTAL
Intervention: Oleogel‐S10
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control
Number of subjects: 32
Study: 28464963

Group type: EXPERIMENTAL
Intervention: Modafinil 200 mg
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: CANTAB
Number of subjects: 74
Study: 26700184

Group type: EXPERIMENTAL
Intervention: 3,4‐methylenedioxymethamphetamine (MDMA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: methylphenidate (MPH)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MDMA/MPH
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MDMA/MPH, MDMA, MPH
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mature NK cells
Number of subjects: 0
Study: 23138387

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Cryoablation (CA)
Number of subjects: 39
Study: 21153402

Group type: EXPERIMENTAL
Intervention: GM‐CSF therapy
Number of subjects: 70

Group type: COMPARATOR
Intervention: Immunoparalysis (TNFα response <200 pg/mL)
Number of subjects: 70
Study: 19036670

Group type: EXPERIMENTAL
Intervention: Tigecycline (initial dose of 100 mg, followed by 50 mg intravenously every 12 hours for 5-14 days)
Number of subjects: 283

Group type: COMPARATOR
Intervention: Imipenem/cilastatin (500/500 mg intravenously every 6 hours for 5-14 days)
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Tigecycline
Number of subjects: 283

Group type: COMPARATOR
Intervention: Imipenem/cilastatin
Number of subjects: 283
Study: 16385401

Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg/day)
Number of subjects: 51
Study: 14532998

Group type: EXPERIMENTAL
Intervention: One arterial infusion of cisplatin
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Two arterial infusions of cisplatin
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: COX‐2 protein expression
Number of subjects: 40